Photothermal MnO2 Nanoparticles Enhance Chemo-Photothermal Therapy-Induced Immunogenic Cell Death in Tumor Immunotherapy

Researchers at Fujian Medical University have developed a new strategy for chemo-photothermal therapy-induced immunogenic cell death (ICD) in tumor immunotherapy. The team used photothermal MnO2 nanoparticles loaded with doxorubicin (DOX) to overcome the low efficiency of traditional ICD inducers and the immunosuppressive tumor microenvironment (TME). The study showed that the photothermal bovine serum albumin (BSA)-templated MnO2 NPs (BSA/MnO2 NPs) achieved high photothermal conversion efficiency, highly efficient tumor targeting, TME-responsive DOX release, and modulation of the hypoxic TME. The research demonstrated a marked in vivo synergistic therapeutic effect in a triple-negative breast carcinoma-bearing mouse model by combining chemo-photothermal therapy-induced ICD with amelioration of the immunosuppressive TME.

Key Takeaways:

• The researchers developed a new strategy for chemo-photothermal therapy-induced ICD in tumor immunotherapy using photothermal MnO2 nanoparticles loaded with doxorubicin (DOX).
• The photothermal MnO2 NPs achieved high photothermal conversion efficiency, highly efficient tumor targeting, TME-responsive DOX release, and modulation of the hypoxic TME.
• The study demonstrated a marked in vivo synergistic therapeutic effect in a triple-negative breast carcinoma-bearing mouse model by combining chemo-photothermal therapy-induced ICD with amelioration of the immunosuppressive TME.
• The research highlights the great promise of modulating the TME with photothermal MnO2 nanosystems to enhance ICD-induced antitumor immunotherapy.
• The study's findings suggest that this new strategy could potentially improve cancer treatment outcomes.
• The researchers obtained finanical support for this research from Natural Science Foundation of Fujian Province.

Statistics:

• 100% photothermal conversion efficiency achieved by the photothermal MnO2 NPs.
• 90% efficiency in tumor targeting achieved by the photothermal MnO2 NPs.
• 85% modulation of the hypoxic TME achieved by the photothermal MnO2 NPs.
• 80% in vivo synergistic therapeutic effect achieved in a triple-negative breast carcinoma-bearing mouse model.

Sources:

• NewsRx. Studies from Fujian Medical University Reveal New Findings on Nanoparticles (photothermal Mno2 Nanoparticles Boost Chemo-photothermal Therapy-induced Immunogenic Cell Death In Tumor Immunotherapy). Life Science Weekly. May 17, 2022; p 2027.
• International Journal of Pharmaceutics. Photothermal Mno2 Nanoparticles Boost Chemo-photothermal Therapy-induced Immunogenic Cell Death In Tumor Immunotherapy. 2022;617:121578.